dc.contributor.author |
Atif, Muhammad |
|
dc.contributor.author |
Bashir, Arslan |
|
dc.contributor.author |
Ahmad, Nafees |
|
dc.contributor.author |
Fatima, Razia Kaneez |
|
dc.contributor.author |
Saba, Sehar |
|
dc.contributor.author |
Scahill, Shane |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2023-08-03T00:42:47Z |
|
dc.date.available |
2023-08-03T00:42:47Z |
|
dc.date.issued |
2017-09 |
|
dc.identifier.citation |
(2017). BMC Infectious Diseases, 17(1), 655-. |
|
dc.identifier.issn |
1471-2334 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/65286 |
|
dc.description.abstract |
<h4>Background</h4>Interim treatment outcomes at 6-months for multidrug-resistant tuberculosis (MDR-TB) treatment are among the most basic performance monitoring and key evaluation indicators in the Stop and End TB strategy of the World Health Organization (WHO). Therefore, this study was conducted to evaluate the interim treatment outcomes of MDR-TB patients in Pakistan.<h4>Methods</h4>This study was conducted at the Programmatic Management Unit for Drug-resistance TB (PMDT) site of the National Tuberculosis Program (NTP), Pakistan. It is located in the Chest Disease Unit (CDU) of the Bahawal Victoria Hospital (BVH), Bahawalpur, Punjab, Pakistan. Data was collected between April 1, 2014 and December 31, 2015. The medical records, Electronic Nominal Recording Reporting System (ENRS) data and MRD-TB notification forms of the MDR-TB patients registered at the PMDT site were reviewed to obtain data. For reporting and calculation of interim treatment outcomes, standardized WHO methodology was adopted. Simple logistic regression analysis was used to examine the possible association between the dependent variable (i.e. unsuccessful interim treatment outcome) and selected socio-demographic and clinical variables.<h4>Results</h4>A total of 100 drug-resistant TB (DR-TB) patients (all types) were registered during the study period. Out of these, 80 were MDR-TB patients for whom interim results were available. Out of the 80 MDR-TB cases, 48 (60%) were classified under the successful interim treatment outcome category. The remaining 40% had unsuccessful 6-month treatment outcomes and 12 (15%) patients died, while nine (11.3%) were lost to follow-up by six months. The final predictors of unsuccessful interim treatment outcomes were; being resistant to ofloxacin (AOR 3.23, 95% CI 0.96-10.89; p-value = 0.04), having above normal baseline serum creatinine levels (AOR 6.49, 95% CI 1.39-30.27; p-value = 0.02), and being culture positive at the second month of treatment (AOR 6.94, 95% CI 2-24.12; p-value = 0.01).<h4>Conclusions</h4>Despite free treatment and programmatic efforts to ensure patient adherence, the high rate of unsuccessful interim treatment outcomes is concerning. The identified risk factors for unsuccessful interim treatment outcomes in the current study provides clinicians an opportunity to identify high-risk patients and ensure enhanced clinical management and greater treatment success rates. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
Springer Nature |
|
dc.relation.ispartofseries |
BMC infectious diseases |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Humans |
|
dc.subject |
Tuberculosis, Multidrug-Resistant |
|
dc.subject |
Creatinine |
|
dc.subject |
Ofloxacin |
|
dc.subject |
Antitubercular Agents |
|
dc.subject |
Treatment Outcome |
|
dc.subject |
Microbial Sensitivity Tests |
|
dc.subject |
Risk Factors |
|
dc.subject |
Retrospective Studies |
|
dc.subject |
Cohort Studies |
|
dc.subject |
Patient Compliance |
|
dc.subject |
Drug Resistance, Multiple, Bacterial |
|
dc.subject |
Adolescent |
|
dc.subject |
Adult |
|
dc.subject |
Middle Aged |
|
dc.subject |
Pakistan |
|
dc.subject |
Female |
|
dc.subject |
Male |
|
dc.subject |
Lost to Follow-Up |
|
dc.subject |
32 Biomedical and Clinical Sciences |
|
dc.subject |
3202 Clinical Sciences |
|
dc.subject |
Infectious Diseases |
|
dc.subject |
Antimicrobial Resistance |
|
dc.subject |
Emerging Infectious Diseases |
|
dc.subject |
Clinical Research |
|
dc.subject |
Prevention |
|
dc.subject |
Lung |
|
dc.subject |
Patient Safety |
|
dc.subject |
Tuberculosis |
|
dc.subject |
Rare Diseases |
|
dc.subject |
Infection |
|
dc.subject |
3 Good Health and Well Being |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.subject |
Clinical |
|
dc.subject |
Clinical Medicine and Science |
|
dc.subject |
0605 Microbiology |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
1108 Medical Microbiology |
|
dc.subject |
3207 Medical microbiology |
|
dc.subject |
4206 Public health |
|
dc.title |
Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1186/s12879-017-2746-5 |
|
pubs.issue |
1 |
|
pubs.begin-page |
655 |
|
pubs.volume |
17 |
|
dc.date.updated |
2023-07-28T22:25:27Z |
|
dc.rights.holder |
Copyright: The authors |
en |
dc.identifier.pmid |
28962599 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/28962599 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
research-article |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
795317 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
Pharmacy |
|
dc.identifier.eissn |
1471-2334 |
|
dc.identifier.pii |
10.1186/s12879-017-2746-5 |
|
pubs.number |
655 |
|
pubs.record-created-at-source-date |
2023-07-29 |
|
pubs.online-publication-date |
2017-09-29 |
|